Ensign Peak Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.45M | Hold |
689,064
| – | – | 0.01% | 584 |
|
|
2025
Q1 | $8.47M | Buy |
689,064
+421,115
| +157% | +$5.17M | 0.02% | 507 |
|
|
2024
Q4 | $3.54M | Sell |
267,949
-93,876
| -26% | -$1.24M | 0.01% | 745 |
|
|
2024
Q3 | $6.97M | Sell |
361,825
-157,060
| -30% | -$3.02M | 0.01% | 542 |
|
|
2024
Q2 | $10.7M | Buy |
518,885
+4,033
| +0.8% | +$82.8K | 0.02% | 435 |
|
|
2024
Q1 | $12.3M | Hold |
514,852
| – | – | 0.02% | 414 |
|
|
2023
Q4 | $11.1M | Hold |
514,852
| – | – | 0.02% | 407 |
|
|
2023
Q3 | $7.48M | Buy |
514,852
+126,500
| +33% | +$1.84M | 0.02% | 464 |
|
|
2023
Q2 | $8.13M | Buy |
388,352
+152,982
| +65% | +$3.2M | 0.02% | 476 |
|
|
2023
Q1 | $4.97M | Hold |
235,370
| – | – | 0.01% | 567 |
|
|
2022
Q4 | $5.99M | Buy |
235,370
+24,002
| +11% | +$611K | 0.01% | 519 |
|
|
2022
Q3 | $5.08M | Buy |
211,368
+85,177
| +67% | +$2.05M | 0.01% | 523 |
|
|
2022
Q2 | $2.43M | Buy |
126,191
+65,454
| +108% | +$1.26M | 0.01% | 737 |
|
|
2022
Q1 | $1.06M | Hold |
60,737
| – | – | ﹤0.01% | 1171 |
|
|
2021
Q4 | $1.33M | Sell |
60,737
-137,865
| -69% | -$3.02M | ﹤0.01% | 1135 |
|
|
2021
Q3 | $3.8M | Buy |
198,602
+142,484
| +254% | +$2.72M | 0.01% | 769 |
|
|
2021
Q2 | $963K | Hold |
56,118
| – | – | ﹤0.01% | 1449 |
|
|
2021
Q1 | $1.25M | Buy |
56,118
+15,141
| +37% | +$338K | ﹤0.01% | 1333 |
|
|
2020
Q4 | $911K | Hold |
40,977
| – | – | ﹤0.01% | 1432 |
|
|
2020
Q3 | $604K | Buy |
40,977
+23,023
| +128% | +$339K | ﹤0.01% | 1480 |
|
|
2020
Q2 | $266K | Buy |
17,954
+6,345
| +55% | +$94K | ﹤0.01% | 1551 |
|
|
2020
Q1 | $127K | Sell |
11,609
-11,610
| -50% | -$127K | ﹤0.01% | 1566 |
|
|
2019
Q4 | $204K | Buy |
+23,219
| New | +$204K | ﹤0.01% | 1615 |
|